Scientists are exploring a new way to harness the medical promise of psychedelic compounds without the mind-bending side effects.

Researchers created modified versions of psilocin — the active form of psilocybin from “magic mushrooms” — that still target key serotonin pathways linked to depression and other brain disorders but appear to cause far fewer psychedelic-like effects.